Related Experiment Video
Updated: Sep 26, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Structural Insights from Molecular Modeling of Isoindolin-1-One Derivatives as PI3Kγ Inhibitors against Gastric
Suparna Ghosh1, Seung Joo Cho1,2
1Department of Biomedical Sciences, College of Medicine, Chosun University, Gwangju 501-759, Korea.
Abstract:
The upregulation of phosphoinositol-3-kinase γ (PI3Kγ) is deemed to be positively correlated with tumor-associated-macrophage (TAM)-mediated gastric carcinoma (GC). PI3Kγ suppresses tumor necrosis factor-alpha (TNF-α) and interleukin-12 (IL-12) through activation of the AKT/mTOR pathway, which promotes the immunosuppressant phenotype of TAM. Unlike α and β isoforms, δ and γ isoforms are primarily distributed in leucocytes and macrophages. Dual inhibitors against PI3Kδ and PI3Kγ have been proven to have merits in targeting solid tumors. Furthermore, it has been found that PI3Kδ is activated by cytokines, while PI3Kγ is activated by G-protein-coupled receptors (GPCRs). This facilitates determining the functional difference between these two isoforms. For this goal, selective inhibitors would be immensely helpful. In the current manuscript, we conducted various molecular modeling studies with a series of isoindolin-1-one derivatives as potent PI3Kγ inhibitors by combining molecular docking, molecular dynamics (MD), molecular mechanics, Poisson-Boltzmann/generalized Born surface area (MM-PB/GBSA) binding free energy calculation, and three-dimensional structure-activity relationship (3D-QSAR) study. To evaluate the selectivity of γ isoform over δ, the molecular modeling studies of idelalisib analogs reported as PI3Kδ inhibitors were also investigated. The contour polyhedrons were generated from the comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) around the ligand-bound active site for both isoforms, which could emphasize plausible explanations for the physicochemical factors that affect selective ligand recognition. The binding modalities of the two isoforms using CoMFA and MD models were compared, which suggested some key differences in the molecular interactions with the ligands and could be summarized as three subsites (one affinity subsite near the C-helix and DFG and two hydrophobic subsites). In the context of the structure-activity relationship (SAR), several new compounds were designed using a fragment-substitution strategy with the aim of selectively targeting PI3Kγ. The pIC50 values of the designed compounds were predicted by the 3D-QSAR models, followed by the MM-PB/GBSA binding energy estimation. The overall findings suggest that the designed compounds have the potential to be used as PI3Kγ inhibitors with a higher binding affinity and selectivity.
Insights
This study developed novel isoindolin-1-one derivatives as selective phosphoinositol-3-kinase gamma (PI3Kγ) inhibitors. Molecular modeling identified key differences between PI3Kγ and PI3Kδ, guiding the design of potent compounds for gastric carcinoma therapy.
Area of Science:
- Medicinal Chemistry
- Computational Chemistry
- Oncology
Background:
- Upregulation of phosphoinositol-3-kinase gamma (PI3Kγ) correlates with tumor-associated macrophage (TAM)-mediated gastric carcinoma (GC).
- PI3Kγ promotes an immunosuppressant TAM phenotype by suppressing TNF-α and IL-12 via AKT/mTOR activation.
- Selective PI3Kγ inhibitors are needed to target cancer, as PI3Kδ and PI3Kγ isoforms have distinct activation mechanisms and distributions.
Purpose of the Study:
- To design and identify potent and selective PI3Kγ inhibitors using molecular modeling.
- To elucidate the structural and physicochemical factors governing PI3Kγ selectivity over PI3Kδ.
- To explore novel isoindolin-1-one derivatives as potential therapeutic agents for PI3Kγ-driven cancers.
Main Methods:
- Employed molecular docking, molecular dynamics (MD), MM-PB/GBSA binding free energy calculations, and 3D-QSAR studies.
- Investigated idelalisib analogs to understand PI3Kδ inhibition and compare binding modalities with PI3Kγ.
- Utilized comparative molecular field analysis (CoMFA) and comparative molecular similarity index analysis (CoMSIA) to generate contour maps and analyze structure-activity relationships (SAR).
Main Results:
- Identified key differences in binding sites and interactions between PI3Kγ and PI3δ isoforms.
- Designed novel isoindolin-1-one derivatives with predicted high binding affinity and selectivity for PI3Kγ using a fragment-substitution strategy.
- 3D-QSAR models successfully predicted inhibitory activity (pIC50) and MM-PB/GBSA confirmed binding energy for designed compounds.
Conclusions:
- The developed molecular modeling approach effectively guided the design of selective PI3Kγ inhibitors.
- The designed isoindolin-1-one derivatives show significant potential as targeted therapeutics for gastric carcinoma.
- Understanding isoform-specific interactions is crucial for developing selective kinase inhibitors with improved efficacy and reduced side effects.
More Related Videos
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Related Concept Videos
Inhibition of Cdk Activity
PI3K/mTOR/AKT Signaling Pathway
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists